Financials
Financial year 2025
LVL MEDIPHAR from Deinze, company number BE0862946642, closed financial year 2025 with a result of € 81,760 after tax. For that financial year LVL MEDIPHAR recorded a gross margin of € 124,150 and equity of € 528,164. Compared with financial year 2024, the result moved from € 96,824 to € 81,760. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on December 31, 2025.
€ 528,164
▲ 4% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 81,760
▼ 16% vs 2024
Profit after tax over the fiscal year.
€ 81,985
▲ 207% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 61,963 paid out
76 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
€ 9,098
▼ 31% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 5,158
▲ 1% vs 2024
Loans from banks and other lenders, long and short.
€ 1,571
▼ 30% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 10,617
▼ 68% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 156,312 | € 108,980 | € 167,357 | € 124,150 | ▼ 26% |
| Profit after taxes | € 80,899 | € 50,389 | € 96,824 | € 81,760 | ▼ 16% |
| Equity | € 442,787 | € 492,376 | € 508,367 | € 528,164 | ▲ 4% |
| Total debts | € 69,425 | € 25,770 | € 62,899 | € 60,450 | ▼ 4% |
| Cash | € 128,306 | € 69,936 | € 26,720 | € 81,985 | ▲ 207% |
| Land & buildings | € 144,131 | € 133,603 | € 123,388 | € 113,306 | ▼ 8% |
| Retained profit | € 424,187 | € 473,776 | € 489,767 | € 509,564 | ▲ 4% |
| Dividend | € 25,800 | € 800 | € 80,833 | € 61,963 | ▼ 23% |
| Bank debt | € 28,533 | € 5,663 | € 5,120 | € 5,158 | ▲ 1% |
| Balance sheet total | € 512,213 | € 518,146 | € 571,266 | € 588,615 | ▲ 3% |
Key figures of LVL MEDIPHAR, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 January 2027.
What happened to LVL MEDIPHAR?
What happened at LVL MEDIPHAR in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 81,760 (▼ 16% vs 2024). Source: NBB ↗
- New establishment in Deinze. KBO
- Start of the company according to the CBE. KBO
In short
From € 80,899 profit in 2022 to € 81,760 profit in 2025.
Paid € 126,757 in corporate taxes since 2022.
Best year ever: 2024, with € 96,824 profit.
Paid out € 169,396 in dividends to the owners in total.
A new publication or filing at LVL MEDIPHAR? We notify you, reason included.
Follow LVL MEDIPHARDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind LVL MEDIPHAR is Lieven Van Landuyt.
Directors
According to the 2025 annual accounts
Lieven Van Landuyt
Director
Establishments
Establishment units
Physical locations of this company
Scheurestraat 7
9850 Deinze
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0862.946.642
- VAT number
- BE 0862.946.642
- Registered office
- Scheurestraat 7, 9850 Deinze
- Names & denominations
- LVL MEDIPHAR
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 23 January 2004
- Peppol
- Active · Active since 30 Sept 2025
- Activities · NACE
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsvoering en beheer
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering